RxDoctor Payments DataLook up a doctor →

David Hensley, MD

Dermatology · Arlington, TXNPI 1144376419

Payments from drug & device makers

$610,039in general payments, 2019–2025

Across 1,901 payments — averaging $320.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$253K
  • Amgen$140K
  • Dermavant Sciences, Inc.$85K
  • Bristol Myers Squibb$43K
  • Sun Pharmaceutical Industries Inc.$35K
  • Lilly USA, LLC$22K
  • plus $33K from 37 others

What the payments were for

  • Consulting fees$8,6682%
  • Speaking & faculty fees$349,53182%
  • Travel & lodging$29,5257%
  • Food & beverage$39,0919%
  • Education$8080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$610,039 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$1,032,350
Medicare patients
1,623
Services billed
31,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa20$420,895
OtezlaApremilast21$99,558
Humira PenAdalimumab13$88,280
Dupixent PenDupilumab16$59,729
VtamaTapinarof13$18,493
ZoryveRoflumilast14$15,158
Clobetasol Propionate137$6,053
Azelaic Acid44$4,437
Fluocinonide125$4,361
Ketoconazole186$4,343
Triamcinolone Acetonide258$4,058
Doxycycline Hyclate306$3,467
Imiquimod103$3,313
Betamethasone Dipropionate93$3,300
Tacrolimus23$2,741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$139,751$99,55821 claims
Dermavant Sciences, Inc.Vtama$84,599$18,49313 claims
Arcutis Biotherapeutics, Inc.Zoryve$442$15,15814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →